Zaltrap (Colorectal Cancer) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 57 Pages
|Zaltrap(大腸癌症):市場預測與分析 Zaltrap (Colorectal Cancer) - Forecast and Market Analysis to 2023|
|出版日期: 2014年11月28日||內容資訊: 英文 57 Pages||
GlobalData has released its new PharmaPoint Drug Evaluation report, "Zaltrap (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.
In 2012, Sanofi/Regeneron's Zaltrap (ziv-aflibercept) was approved by the FDA in combination with FOLFIRI for the treatment of metastatic CRC that has become resistant or progressed on prior oxaliplatin-containing combination therapy (FDA, press release, August 3, 2012). This was followed by European approval in February 2013 (Sanofi and Regeneron, press release, February 5, 2013).